Blackrock, INC Schedule 13G passive stakes

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.0% beneficial ownership stake in Compass Therapeutics, Inc. as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.0% of Elanco Animal Health Inc's common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.4% of Elevation Oncology, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has reported a beneficial ownership of 5.3% of Entrada Therapeutics, Inc.'s common stock as of December 31, 2024, in a routine Schedule 13G filing.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.2% beneficial ownership stake in Fractyl Health, Inc. as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing a 9.9% beneficial ownership stake in FrontView REIT, Inc. as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.3% beneficial ownership stake in Guardian Pharmacy Services, Inc. as of December 31, 2024.

BlackRock, Inc. has reported a passive beneficial ownership of 5.7% of Inhibrx Biosciences, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a 6.2% beneficial ownership stake in iShares MSCI Singapore ETF as of December 31, 2024, held for ordinary course of business.

BlackRock, Inc. has filed a Schedule 13G, revealing a passive beneficial ownership of 5.5% of Lexeo Therapeutics, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing a passive beneficial ownership of 5.2% of Lyft, Inc.'s Class A common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 6.3% of Monte Rosa Therapeutics, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing a 9.0% passive beneficial ownership stake in Shift4 Payments Inc. as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing its beneficial ownership of 5.5% of TransUnion's common stock as of December 31, 2024.

Investment giant BlackRock, Inc. has reported a 5.3% passive beneficial ownership stake in biotechnology firm Viking Therapeutics, Inc. as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7.3% of Applied Digital Corp's common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing an 8.7% beneficial ownership stake in BILL Holdings, Inc. as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.7% in the Common Stock of BLACKROCK ETF TRUST II CL1 as of December 31, 2024.

BlackRock, Inc. has reported a 5.0% beneficial ownership stake in Comstock Resources Inc. as of December 31, 2024, held for investment purposes.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in Coty Inc.'s Class A securities as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.5% beneficial ownership stake in Liberty Broadband Corp as of December 31, 2024, held in the ordinary course of business.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in National Research Corp as of December 31, 2024, held for ordinary course investment purposes.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.6% beneficial ownership stake in Pyxis Oncology, Inc. as of December 31, 2024.

BlackRock, Inc. has reported a 5.5% beneficial ownership stake in ASP Isotopes Inc., holding 3,955,388 shares of common stock as of December 31, 2024.

BlackRock, Inc. has filed a Schedule 13G, revealing a beneficial ownership of 5.2% of the common stock of ADC Therapeutics SA as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 3.6% of Semler Scientific, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 4.5% passive beneficial ownership stake in Samsara Inc.'s Class A Common Stock as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 2.6% in Seaport Entertainment Group Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 14.6% beneficial ownership stake in WAFD INC as of December 31, 2024.

BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, reporting a beneficial ownership of 11.6% in Northfield Bancorp, Inc. as of December 31, 2024.